Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study

BACKGROUND: The California Cancer Consortium has performed a Phase II trial of infusional bryostatin, a protein kinase C inhibitor isolated from the marine invertebrate bryozoan, Bugula Neritina, a member of the phylum Ectoprocta, in combination with cisplatin, in patients (pts) with recurrent plati...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Morgan, Robert J., Leong, Lucille, Chow, Warren, Gandara, David, Frankel, Paul, Garcia, Agustin, Lenz, Heinz-Josef, Doroshow, James H.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3751394/
https://ncbi.nlm.nih.gov/pubmed/20936324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9557-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky